Finland – Pharmaceutical products – Retinfanlimabin hankinta
HUS-yhtymä
Buyer country
Finland
Publication date
15 October 2026
Biderra sector
Pharma and laboratory
Data source
TED open data
Decision signals
First-pass opportunity review
These signals are calculated from the indexed fields. They help prioritize a review but do not replace eligibility checks in the official procurement documents.
- Timing signal
- Deadline not indexed
- Indexed data completeness
- 71%
- Official title coverage
- 7 languages
- Classification signal
- 33600000
- 90-day market activity
- 31 related notices
- Buyer activity
- 96 indexed notices
Check the official notice
Based on seven decision fields
Preserved from source-supplied versions
Medical equipment, pharmaceuticals and personal care products
14 buyers in Finland / Pharma and laboratory
Published by this buyer in the last 90 days
Market context
How this notice compares with the current market
Biderra found 31 pharma and laboratory notices from Finland in its rolling 90-day index. 16% publish an estimated value and 19% include at least one indexed deadline. This notice is not currently active according to the deadline fields available in the source feed.
Recent notices
31
Value disclosed
16%
Deadline coverage
19%
Related active opportunities
More pharma and laboratory notices from Finland
Tulli · CPV 38433100
24 days to indexed deadline · 27 November 2026
HUS Group, the joint authority for Helsinki and Uusimaa · CPV 33696500
6 days to indexed deadline · 09 November 2026
Official title versions
TED may publish the same notice title in several official languages. Biderra preserves the versions supplied in the source feed.
Finlandia – Productos farmacéuticos – Retinfanlimabin hankinta
Finland – Farmaceutische producten – Retinfanlimabin hankinta
Finlandia – Produkty farmaceutyczne – Retinfanlimabin hankinta
Finlande – Produits pharmaceutiques – Retinfanlimabin hankinta
Finnland – Arzneimittel – Retinfanlimabin hankinta
Finlandia – Prodotti farmaceutici – Retinfanlimabin hankinta
Finland – Pharmaceutical products – Retinfanlimabin hankinta
What Biderra adds
For notice 711376-2026, Biderra has normalized the contracting authority country as Finland, grouped CPV 33600000 under pharma and laboratory, compared the available deadline fields with today, measured field completeness, and preserved 7 source-supplied title versions. The official record remains decisive.